Moxifloxacin in multidrug-resistant tuberculosis: is

Fluoroquinolones are rapidly emerging as important drugs in the treatment of tuberculosis (TB) worldwide [1]. In drugsusceptible TB, their use is currently under investigation and, according to the American Thoracic Society/Centers for Disease Control guidelines, fluoroquinolones are indicated only in patients receiving the conventional regimen who present severe adverse reactions [2]. However, in drug-resistant (DR) and, more specifically, in multidrug-resistant (MDR)-TB, the role of fluoroquinolones is much better established. Later-generation fluoroquinolones are included even in extensively drug resistant (XDR)-TB regimens since they may have some efficacy against ofloxacin-resistant strains [3].